Y-mAbs Therapeutics' Q2 revenue falls 14%

Y-mAbs Therapeutics

08/08/2025 11:44

Overview

Y-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectations

SERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025

Co's acquisition agreement approved by Y-mAbs Board, tender offer by Aug. 19

Outlook

Y-mAbs did not provide further guidance due to pending acquisition

Company to be acquired by SERB Pharmaceuticals by Q4 2025

Result Drivers

U.S. REVENUE DECLINE - Driven by lower patient volume due to clinical study enrollments and increased competition

EX-U.S. REVENUE DROP - Attributed to absence of stocking orders from Western Europe and Eastern Asia

LICENSE REVENUE - $0.5 mln recognized from sales-based milestone achievements in Israel

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
$19.50 mln
Q2 EPS
Beat
-$0.07
-$0.27 (9 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $8.60, about 0.9% above its August 7 closing price of $8.52

Press Release: ID:nGNX47pmBL

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)